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Abstract
Background: Kisspeptins and their G-protein coupled receptor, GPR54 are required for GnRH
release and have been associated with anti-metastatic tumour cell behaviour in model systems. The
latter might suggest that their overexpression would be associated with a better prognosis in
cancer. However, kisspeptin/GPR54 interactions (autocrine, paracrine, and/or endocrine) could
also impact tumour behaviour in a negative manner. Here, for the first time, we associate the
immunoreactivity of the kisspeptin/GPR54 ligand-receptor pair with favourable prognosis in a large
cohort of ovarian carcinomas.
Methods: Immunohistochemical analysis for kisspeptin and GPR54 was performed on a tissue
microarray (TMA) consisting of 518 early stage ovarian carcinomas, all with linked clinical outcome
data. The TMA was scored using a staining intensity scale of 0 (negative), +1 (mild-moderate), and
+2 (strong). Strong staining cases were considered either kisspeptin or GPR54 positive and
designated as 1, while all other cases were considered negative and designated 0. All statistical
analysis was conducted using two-sided tests and a p value equal to or less than 0.05 was
considered significant.
Results: Kisspeptin and GPR54 immunoreactive cases show a favourable prognosis in univariable
disease specific survival (p = 0.0023, p = 0.0092), as well as in overall survival (p = 0.0006, p =
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0.0002). Furthermore, kisspeptin is an independent marker for favourable prognosis as determined
by multivariable disease specific (p = 0.0046) and overall survival analysis (p = 0.0170), while GPR54
is an independent marker for overall survival only (p = 0.0303). Both kisspeptin positive and GPR54
positive cases are strongly associated with the ovarian carcinoma clear cell subtype (p < 0.0001, p
< 0.0001), and GPR54 is significantly associated with favourable prognosis in overall survival within
the clear cell subtype (p = 0.0102).
Conclusion: Kisspeptin and GPR54 immunoreactivity are significantly associated with favourable
prognosis in both disease specific and overall survival, as well as being significantly associated with
the clear cell ovarian carcinoma subtype, thereby creating the first independent prognostic
biomarkers specific for ovarian clear cell carcinomas.
Background
The early diagnosis and management of ovarian cancer is
a major area of unmet medical need. Central to the lack of
progress in clinical management has been the virtual
absence of prognostic or predictive molecular markers for
ovarian cancer. Key to addressing these questions is the
availability of sufficiently large, clinically annotated tissue
microarrays (TMA) that offer the prospect of defining the
prognostic or predictive value of any given molecular
marker. Therefore we have constructed a large ovarian
cancer TMA (518 patients) with associated clinical demo-
graphic and outcome information and have used this to
systematically address the value of possible biomarkers of
disease prognosis. In the present study, we have tested the
prognostic value of kisspeptin and GPR54 immunoreac-
tivity in ovarian cancer. Kisspeptins (Kp-54, Kp-14, Kp-13,
Kp-10) are the canonical, physiologically occurring and
high affinity RF-amide peptide ligands that activate trans-
membrane signalling via a classical (7TM1) family G-pro-
tein coupled receptor, GPR54. Kisspeptins were first
discovered through microcell-mediated chromosome
transfer experiments that defined the KiSS-1 locus as a
suppressor of melanoma tumour metastasis [1,2]. Subse-
quently, kisspeptins were associated as endogenous lig-
ands for the GPR54 receptor. Furthermore, a physiological
role in the regulation of placental trophoblast invasion
has been suggested [3] and in migratory cell lines, activa-
tion of GPR54 signalling abrogates migratory behaviour
[1,4-6]. Specifically overexpression of KiSS-1 in an ovarian
cell line expressing endogenous GPR54 suppressed its
metastatic phenotype [7].
In 2003, we uncovered in human and mouse genetic stud-
ies, the major physiological functions of kisspeptin-
GPR54 signalling, as being gatekeepers for GnRH release
in the hypothalamus [8,9]. In the absence of functional
kisspeptin [10] and GPR54 [9,11-13] neither humans nor
mice undergo puberty and are unable to generate pituitary
release of gonadotropins that drive sex-steroid release.
Several subsequent physiological studies have confirmed
that kisspeptins act as neuroendocrine peptides that
switch on or off the GnRH axis in humans and mammals
[14-25], and are thus required as physiological regulators
of sex-steroid release. The mechanistic relationship
between GPR54 regulation of the hypothalamic-pituitary-
gonadal axis, and possible effects on epithelial cell migra-
tion remains unclear, however several anecdotal studies
on human tumours have suggested possible associations
of loss/absence of expression, with poor prognosis [26-
33]. Recently, Zhang et al [34] and Hata et al [35] surveyed
RNA expression of the KiSS-1 and GPR54 loci in small
cohorts (< 100 cases) of ovarian cancer and observe a
trend towards favourable prognosis where KiSS-1/GPR54
RNA expression is elevated. None of these studies have
been sufficiently powered to address cell type and prog-
nostic associations in major epithelial malignancies. We
show in the present study of 518 ovarian cancer cases that
kisspeptin and GPR54 immunoreactivity are very signifi-
cantly associated with a clear cell carcinoma subtype, and
that both kisspeptins and GPR54 are independent mark-
ers for favourable prognosis as determined by multivaria-
ble analysis.
Methods
Ovarian tumour samples and TMA construction
Approval for the study was obtained from the ethics com-
mittee of the University of British Columbia. Most
women diagnosed with ovarian cancer in British Colum-
bia are treated at the British Columbia Cancer agency
(BCCA) and provincial treatment guidelines are followed.
Outcomes are tracked via The Cheryl Brown Ovarian Can-
cer Outcomes Unit as an ovarian cancer database of the
BCCA. A total of 3501 patients with invasive epithelial
ovarian carcinoma were referred to the BCCA between
1984 and the year 2000. The focus of this study was 834
patients who had ovarian carcinoma with no macroscopic
residual disease after surgery. For 202 cases, the slides of
the primary ovarian tumour were not available for review
and these cases are excluded. A gynaecological pathologist
(CBG) then did a blinded full slide review of the remain-
ing 632 cases. Tumour cell type and grade (Silverberg)
were assessed; all clear cell carcinomas were considered to
be grade 3, as per World Health Organization recommen-
dations. After review, 518 cases of invasive ovarian carci-BMC Medicine 2007, 5:33 http://www.biomedcentral.com/1741-7015/5/33
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noma were available in tissue blocks for tissue microarray
construction. A representative area of each tumour was
selected and a duplicate core TMA was constructed
(Beecher Instruments, Silver Springs, MD, USA); the
cohort is described in Table 1. Serial 4 µm sections were
cut for immunohistochemical (IHC) analysis.
Immunohistochemistry
Kisspeptin
Sections from formalin-fixed and paraffin-embedded tis-
sues were deparaffinized with xylene and rehydrated with
a graded series of alcohols. Wet heat-induced antigen
retrieval was performed in a steamer for 20 min with a
modified citrate buffer (pH 6.1, Dako, Mississauga,
Ontario, Canada). Following antigen retrieval, sections
were treated with 3% hydrogen peroxide (H2O2) in phos-
phate buffered saline (PBS) for 30 min to quench endog-
enous peroxidase activity. All of the aforementioned steps
were followed by three washes with PBS for 5 min each.
Slides were subsequently blocked for 30 min with serum-
free protein block (Dako) and incubated overnight at 4°C
with a polyclonal goat anti-(KiSS-1) antibody (C-20,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted
1:400 in serum-free protein block. Kisspeptin immunore-
activity (IR) was detected with the CSA II biotin-free tyra-
mide signal amplification system and 3,3'-
diaminobenzidine chromogen solution (Dako). Specifi-
cally, rabbit anti-goat horseradish peroxidase conjugate
(HRP) was applied for 15 min followed by fluorescyl-tyra-
mide amplification reagent for 15 min and anti-fluores-
cein HRP for 15 min. All of the steps subsequent to the
incubation with primary antibody were followed by three
washes with Tris-buffered saline containing 1% Tween
(TBST) for 5 min each. Slides were counterstained with
Harris hematoxylin (Sigma-Aldrich, Oakville, Ontario,
Canada) and mounted in a xylene-based mounting
medium. Based on previously published data showing
cell-type restriction of GPR54 and kisspeptins in different
trophoblast layers of human placenta [3], less than 10-
week old human placenta was used as a specificity control
(courtesy of Vancouver Coastal Health archives), in con-
junction with two blocking peptides (21 residues and 54
residues; Figure 1). Omission of the primary antibody was
used as a negative control.
GPR54
TMA 4 µm sections were processed using a Ventana Dis-
covery XT automated system (Ventana Medical Systems,
Tucson, AZ, USA) as per manufacturer's protocol with
proprietary reagents. After slides were baked at 60°C for 1
h, they were deparaffinized on the automated system with
EZ Prep solution (Ventana). Heat-induced antigen
retrieval method was used in Cell Conditioning solution
(CC1-Tris based EDTA buffer, pH 8.0, Ventana). The pol-
yclonal rabbit GPR54 antibody was obtained from MBL
International Corporation (Woburn, MA, USA) specific
for the N-terminal extracellular domain (catalogue
number LS-A1929) and used with heat at a 1:25 concen-
tration in Ventana antibody diluent. The Ventana Univer-
sal Secondary Antibody was used for 32 min at 37°C. The
detection system used was the Ventana DABMap kit, and
slides were then counterstained with Hematoxylin and
treated with a proprietary bluing agent (Ventana). All
washes were conducted with the Ventana Reaction Buffer.
Dehydration steps and coverslip procedure were com-
pleted manually as per manufacturer's recommendations.
Specificity was determined by Western blot (Additional
file 1) and by using less than 10-week old human placenta
as a positive control (Figure 1) and omission of primary
antibody as a negative control.
Photomicrographs
The TMA was digitally scanned with a BLISS (Bacus Labo-
ratories Inc., Slide Scanner) automated system (Bacus Lab-
oratories, Lombard, IL, USA) as previously described [36].
These images are available on our webslide server that is
publicly available [37].
Statistical analysis
Survival time dependant recursive partitioning was used
to binarise the raw kisspeptin and GPR54 data. Univaria-
ble survival analysis was performed by the generation of
Kaplan-Meier curves [38] and differences between the
groups were assessed using Log-rank Statistic [39]. Multi-
variable survival analysis was performed using the Cox
Proportional Hazards Model [39,40]; the adenocarci-
Table 1: Clinicopathological characteristics of the cohort
Parameter N
Histopathological subtype
Adenocarcinoma 4
Clear cell 132
Endometrioid 125
Mucinous 31
Serous 212
Squamous cell 1
Transitional 6
Undifferentiated 7
Grade
1 106
2 114
3 298
Stage
1 214
2 219
38 5
Age (years)
Mean (SD) 58 (12.8)
Median 57
Range (min-max) 25–89BMC Medicine 2007, 5:33 http://www.biomedcentral.com/1741-7015/5/33
Page 4 of 12
(page number not for citation purposes)
noma, squamous cell, transitional, and undifferentiated
ovarian subtypes were excluded from multivariable anal-
ysis due to insufficient sample size. Contingency tables
and the Pearson Chi-square statistic were used to test the
change in the distribution of kisspeptin and GPR54
expression across primary cell types [41]. All analyses were
performed using JMP version 6.0.3 (SAS Institute, Cary
NC, USA).
IHC controls Figure 1
IHC controls. Less than 10-week-old human placenta used as a positive control. (A) Kisspeptin-IR shows intense cell-type 
specific staining in the syncytiotrophoblasts (black arrow), while the cytotrophoblast layers remain unaffected (black arrow-
head). (B) GPR54-IR shows intense staining in the villous cytotrophoblasts (black arrow), the extravillous cytotrophoblasts 
(black arrowhead), and moderate staining on the syncytiotrophoblast membrane (grey arrow). (C) Schematic of the 1–145 
amino acid (aa) KiSS-1 pro-peptide. Metastin (Kp-54) is encoded within the 68–121 aa sequence, while Kp-10 is encoded within 
this same region from 112–121 aa. The specific blocking peptide is encoded within the 100–120 aa sequence. (D) Varying 
kisspeptin-IR was found among the different blocking peptides used. Blocking the primary antibody with full-length metastin 
(Kp-54) and blocking peptide resulted in complete loss of immunoreactivity, while Kp-10 was unable to block any detectable 
staining.BMC Medicine 2007, 5:33 http://www.biomedcentral.com/1741-7015/5/33
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Results
Kisspeptin positivity is an independent marker for 
favourable prognosis
Kisspeptin-IR was tested on human placenta less than 10
weeks old as a positive control (Figure 1). There was cell
type specificity demonstrated by intense staining in syncy-
tiotrophoblast cells as previously determined [3,42], but
not in other cell layers of the trophoblast. Pre-absorption
with two different blocking peptides (metastin (Kp-54,
68–121 amino acids (aa)) and kisspeptin 100–120 aa),
fully blocked kisspeptin-IR, whereas Kp-10 (112–121 aa)
showed little or no block (Figure 1).
For the 518 case ovarian tissue microarray, kisspeptin-IR
was scored as 0 for negative cases, +1 for mild staining,
and +2 for intense staining (Figure 2). Of the 518 cases, 44
stained at +2, 98 had +1 staining intensity, 354 cases were
negative for kisspeptin-IR, and 22 cases were uninterpret-
able. The negative (0) and mildly reactive (+1) cases were
grouped for statistical analysis and assigned the designa-
tion 0 and considered kisspeptin negative, while the +2
cases were considered kisspeptin positive and designated
as 1. Univariable disease specific survival analysis showed
that kisspeptin-IR significantly associated with favourable
prognosis (p = 0.0023), as did overall survival (p =
0.0006, Figure 3). Further, multivariable survival analysis
including; stage, grade, histological subtype, age and
GPR54-IR, indicated kisspeptin-IR as an independent
marker for favourable prognosis in disease specific (p =
0.0046, Table 2) and overall survival (p = 0.0170, Table
3).
GPR54 positivity is an independent marker for favourable 
prognosis in overall survival
The GPR54 antibody and protocol were tested on less
than 10-week old human placenta and specifically stained
both villous and extravillous cytotrophoblasts and the
syncytiotrophoblasts as described by previous groups
[3,42] (Figure 1). Although GPR54 is a 7-transmembrane
protein, there was some reactivity in the cytoplasm of
Immunoreactivity patterns Figure 2
Immunoreactivity patterns. Three types of kisspeptin-IR (A-C) and GPR54-IR (D-F) observed in the ovarian TMA. (A, D) 
Representative samples of negative cases show complete lack of staining and are classified as 0. (B) Moderate GPR54-IR shows 
a patchy staining pattern with light and dark brown regions of reactivity shown throughout the tumour core, and (E) Mild 
kisspeptin-IR shows uniform light brown staining throughout the sample: both B and E are classified as +1 immunoreactivity. 
(C, F) Examples of +2 intense immunoreactivity exhibit dark brown staining in all tumour cells. Scale bar represents 100 µm. 
Insets in each panel show a more detailed view of the staining pattern that is demonstrated in the larger image; inset scale bar 
represents 25 µm.BMC Medicine 2007, 5:33 http://www.biomedcentral.com/1741-7015/5/33
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some tumour cells (this is not entirely surprising as
GPR54 is a transmembrane protein and can be recycled
through the cytoplasm) but only membranous staining
was taken into consideration while assessing immunore-
activity. Three immunoreactivity patterns were observed
within the TMA for GPR54. Specifically, negative or very
weak reactivity in less than 5% of cells was designated as
0 (103 cases), while patchy or moderate staining in 5–
75% of cells was designated +1 (282 cases), and strong
staining in greater than 75% of cells were considered +2
(104 cases, Figure 2). The remaining nine cases were unin-
terpretable. As with kisspeptin, the 0 and +1 GPR54 cases
were group together and considered as loss of receptor
and designated 0, while the strong staining +2 cases were
considered positive and designated as 1. Univariable sur-
vival analysis determined GPR54 as a significant marker
for favourable prognosis in disease specific (p = 0.0092)
and overall survival (p = 0.0002, Figure 3). Similar to
kisspeptin-IR, GPR54 maintained significance in multi-
variable overall survival (p = 0.0303, Table 3). However,
GPR54 was not found to be a significant independent
marker in disease specific survival (p = 0.1118, Table 2).
Kisspeptin positivity correlates with GPR54 positive cases
Kisspeptin positive cases had a moderate correlation with
GPR54 positivity as determined by Kendall's tau-b [43] (τ
= 0.3837, p < 0.0001). There were 31 cases that were both
kisspeptin and GPR54 positive, 90 cases that were
kisspeptin negative and GPR54 positive, 12 cases with
kisspeptin positivity and had loss of GPR54, 356 cases
that had loss of both kisspeptin and GPR54, and the
remaining 29 cases were uninterpretable. When kisspep-
tin-IR and GPR54-IR cases are grouped together (G+ K+),
patients have a more favourable outcome than those that
have loss of either one or both (G- K+, G+ K-, G- K-). There
is a significant difference between survival for double pos-
itive patients (G+ K+) as compared to double negative
patients (G- K-) in both disease specific (p = 0.0067) and
overall survival (p = 0.0002, Figure 3).
Kisspeptin and GPR54 positive staining are significantly 
associated with clear cell carcinoma histopathological 
subtype
The percentage of kisspeptin and GPR54 positive cases
within each histopathological subtype is listed in Table 4.
The proportionality of primary histopathological cell type
in the entire cohort, kisspeptin positive cases, and GPR54
positive cases are represented in Table 5. Testing for an
association between ovarian carcinoma subtype and
kisspeptin status, there was a highly significant positive
association with clear cell carcinoma, and a significant
negative association with serous carcinoma subtype (χ2, p
< 0.0001). GPR54 positive cases also had a significant
positive association with clear cell carcinoma subtype and
a negative association with the serous subtype (χ2, p <
0.0001).
When disease specific survival and overall survival were
analyzed within each ovarian carcinoma subtype, the log-
rank test for kisspeptin-IR status failed to achieve signifi-
Table 3: Multivariable overall proportional hazards
Parameter Risk ratio (95% CI) p Value
Stage < 0.0001
1 0.7258 (0.5842 to 0.8961)
2 0.7149 (0.6457 to 0.9476)
3 1.0000
Histological grade 0.5356
1 0.8268 (0.5818 to 1.1642)
2 1.1113 (0.8647 to 1.4148)
3 1.0000
Subtype 0.6763
Clear cell 1.2126 (0.7934 to 1.8513)
Endometrioid 0.8120 (0.5508 to 1.1914)
Mucinous 1.0192 (0.5652 to 1.6841)
Serous 1.0000
Age < 0.0001
N/A
GPR54 0.0303
Positive 0.5959 (0.3684 to 0.9523)
Negative 1.0000
Kisspeptin 0.0170
Positive 0.4844 (0.2443 to 0.8841)
Negative 1.0000
*RR for age is not available because it is a continuous variable.
Table 2: Multivariable disease specific proportional hazards
Parameter Risk ratio (95% CI) p Value
Stage < 0.0001
1 0.6404 (0.4901 to 0.8278)
2 0.7149 (0.5647 to 0.8994)
3 1.0000
Histological grade 0.0720
1 0.6234 (0.3829 to 0.9808)
2 1.3899 (1.0193 to 1.8888)
3 1.0000
Subtype 0.2508
Clear cell 1.4519 (0.8853 to 2.3847)
Endometrioid 0.6804 (0.4105 to 1.1032)
Mucinous 1.0721 (0.5119 to 1.9699)
Serous 1.0000
Age 0.0747
N/A
GPR54 0.1118
Positive 0.6475 (0.3738 to 1.1052)
Negative 1.0000
Kisspeptin 0.0046
Positive 0.3508 (0.1426 to 0.7408)
Negative 1.0000
*RR for age is not available because it is a continuous variable.BMC Medicine 2007, 5:33 http://www.biomedcentral.com/1741-7015/5/33
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Disease specific (left) and overall (right) survival curves for kisspeptin and GPR54 Figure 3
Disease specific (left) and overall (right) survival curves for kisspeptin and GPR54. The top two graphs demon-
strate the significant survival curves for GPR54, while the middle two graphs demonstrate kisspeptin related survival. For the 
bottom two graphs, the p value refers to the distance between the GPR54 positive/kisspeptin positive cases (G+ K+, solid light 
grey) and the GPR54 negative/kisspeptin negative cases (G- K-, solid dark grey).BMC Medicine 2007, 5:33 http://www.biomedcentral.com/1741-7015/5/33
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cance (due to insufficient sample size), although for the
clear cell cases statistical significance was approached (p =
0.1042, p = 0.0859, results not shown). Of note, none of
the kisspeptin positive patients that were not clear cell
subtype (16 cases) died from their disease. Similarly,
when assessing GPR54 positivity within each ovarian can-
cer subtype, disease specific survival did not reach signifi-
cance within the clear cell subtype (p = 0.0656), although
significance was achieved for overall survival (p = 0.0102,
Figure 4).
Discussion
Although clear cell carcinomas comprise fewer than 5% of
ovarian malignancies, they are notoriously difficult to
treat due to their tendency to resist platinum based chem-
otherapy [44]. To date, clinical stage has been the only
prognostic marker for clear cell ovarian carcinoma. Here
we show for the first time, that kisspeptin and GPR54
immunoreactivities mark distinctly for favourable prog-
nosis, with kisspeptin being independent of pathologic
subtype, stage, grade, or age in both overall and disease
specific survival, while GPR54 is an independent marker
in overall survival. Within clear cell carcinomas, GPR54
expressers have a favourable prognosis and to our knowl-
edge this is the first molecular marker of prognosis specif-
ically applicable to clear cell ovarian cancer. Although
several studies have suggested possible relationships
between GPR54 and kisspeptin expression and clinical
outcome [26,27,30-34,45], these studies have consisted of
smaller cohorts and while some associations have been
noted, some studies might not have been sufficiently
powered to address possible prognostic or cell type spe-
cific effects with rigour. To date, the present study is the
largest systematic analysis of GPR54 and kisspeptin
expression determined by immunoreactivity for an epi-
thelial malignancy. In part, this could be due to difficul-
ties in obtaining sufficiently specific antisera and
detection protocols, in that short peptides and GPCRs are
notoriously difficult antibody targets. The antibodies and
immunodetection protocols used in this study were veri-
fied by the use of either Western blotting and cell-type
specific expression (GPR54), or cell-type specific expres-
sion and specific blocking peptides (kisspeptin). This is
based on previous work showing differential expression
of kisspeptin and GPR54 in human placental trophoblast
cell types [3,45]. We note that while Muir et al [46] dem-
onstrated a 75 kDa fragment as GPR54 by Western blot,
our data show a fragment much closer to the predicted
42.5 kDa molecular weight for GPR54. The basis of this
difference is unknown, but could result from post-transla-
tional modification arising in different tissues (brain vs
tumour cell lines). Although blocking peptides suggest
specificity of the antisera used, the precise spectrum of
immunoreactivity of the kisspeptin antiserum to kisspep-
tin fragments remains to be determined. As with many
antibodies, it remains possible that other proteins could
be detected however this does not diminish their utility as
markers of prognosis. Very recently a survey of 76 ovarian
cancer patients using Q-PCR detection of GPR54 and
kisspeptin transcripts [35] demonstrated a negative corre-
lation between KiSS-1 and GPR54 mRNA levels with
residual disease, although they showed no correlation
with histopathological subtype (possibly due to the rela-
tively small number of clear cell ovarian cancers in that
cohort), however the overall correlation observed in this
study is in agreement with our observations.
The mechanisms responsible for the association of
kisspeptin and GPR54 expression with disease behaviour
in ovarian cancer requires definitive studies, however sev-
eral possibilities arise. It is possible that expression of
kisspeptins and/or GPR54 result in higher endogenous
GPR54 signalling in malignant cells. Although no studies
have directly addressed the degree of GPR54 signalling in
epithelial malignancies in relation to clinical outcomes,
the present study shows that both kisspeptin and GPR54
expression are associated with a better prognosis. Further-
more, patients with double positive tumours (G+ K+)
have the most favourable prognosis (Figure 3). These
observations together with previous evidence of the effects
of GPR54 signalling on cell migration, suggest some form
of autocrine or paracrine loop could exist in clear cell car-
cinomas. GPR54 is exquisitely sensitive to kisspeptin lig-
and stimulation [3,5] and receptor overexpression alone
might be enough to increase basal signalling through
GPR54.
The interplay of mechanisms could be complicated by the
major physiological role of GPR54, which is to regulate
GnRH secretion at the hypothalamic level. Kisspeptins
can cross from the peripheral circulation to act on the
hypothalamus, as has been shown in numerous mamma-
lian [22,24,47-49] and one human study [21]. It is possi-
ble that kisspeptin overexpressing tumours could result in
stimulation of the hypothalamic-pituitary axis, resulting
in the release of gonadotropins and other derived pep-
tides with a possible paracrine/endocrine effect on
tumour growth. Indeed Nash et al [50], have shown that
melanoma cells unable to signal on exposure to
Table 4: Percentage of kisspeptin and GPR54 positive cases 
within the histological subtypes
Histological 
subtype
Kisspeptin 
positive (%)
GPR54 
positive (%)
Clear cell 21.88 66.41
Endometrioid 8.13 20.33
Mucinous 12.00 10.34
Serous 1.49 3.37BMC Medicine 2007, 5:33 http://www.biomedcentral.com/1741-7015/5/33
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kisspeptins, can still be suppressed from metastasis by
exogenous kisspeptin, suggesting that paracrine effects
could operate in these cases. Finally, some evidence sug-
gests that kisspeptins and GPR54, which are expressed in
ovarian epithelium and granulosa cells, might co-modu-
late the activity of gonadotropins in sex steroid release
[42]. If such a mechanism were operational in clear cell
ovarian cancers, it would imply that tumour behaviour is
also linked to co-modulatory peptides.
Beyond the salient observation of prognostic significance
in this study, the nature of the proteins involved suggests
a number of possible areas for intervention. First,
kisspeptins, the products of the KiSS-1 gene locus, are nat-
urally occurring peptides that can be detected in human
serum and other tissues [51-53]. It is possible that serum
kisspeptide levels could be developed as a biomarker of
disease activity in patients with clear cell carcinoma. How-
ever, diagnostic grade antibodies would have to be devel-
oped before routine immunohistochemical-based
analysis of kisspeptin and GPR54 could be undertaken.
Secondly, kisspeptins are naturally occurring peptide hor-
mones that have activity in humans [21]. As such they are
highly amenable to use as therapeutic agents, either alone
or as modified peptides. We anticipate that the strong
association of GPR54 and kisspeptin expression with out-
come and clear cell type in ovarian carcinoma will stimu-
late fresh approaches to what is still a lethally intractable
disease.
Conclusion
Kisspeptin and GPR54 are significantly associated with
favourable prognosis in both disease specific and overall
survival, as well as being significantly associated with the
clear cell ovarian carcinoma subtype, thereby creating the
first independent prognostic biomarkers specific for ovar-
ian clear cell carcinomas.
Table 5: Kisspeptin and GPR54 proportions within the cohort
Histological subtype Whole cohort Kisspeptin positive GPR54 positive
Proportion Count Proportion Count Proportion Count
Clear cell 0.2640 132 *0.6364 28 **0.7131 87
Endometrioid 0.2500 125 0.2273 10 0.2049 25
Mucinous 0.0620 31 0.0682 3 0.0246 3
Serous 0.4240 212 *0.0682 3 **0.0574 7
*χ2 p value < 0.0001
**χ2 p value < 0.0001
Kaplan-Meier disease specific (left) and overall (right) survival curves for GPR54 positivity within the clear cell subtype Figure 4
Kaplan-Meier disease specific (left) and overall (right) survival curves for GPR54 positivity within the clear cell subtype.BMC Medicine 2007, 5:33 http://www.biomedcentral.com/1741-7015/5/33
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